2006
DOI: 10.1590/s1676-24442006000400008
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: O presente estudo objetivou avaliar a expressão de BCL-2 e BAX em tumores astrocíticos humanos. Material e métodos: Procedeu-se ao estudo imuno-histoquímico dessas proteínas utilizando-se o método da avidina-biotina-peroxidase em 55 astrocitomas (13 do grau I, 14 do II, sete do III e 21 do grau IV) e cinco amostras de tecido cerebral não-tumoral (grupo controle). Resultados: Os índices de positividade para BCL-2 e BAX demonstraram propensão ao acréscimo, de acordo com a gradação tumoral, com positividade geral… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0
2

Year Published

2011
2011
2021
2021

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 14 publications
0
3
0
2
Order By: Relevance
“…Considering these two targets are antagonistic in the apoptosis pathway, BAX:BCL-2 expression ratios were calculated to define the apoptotic profile of both cell lines in response to cisplatin and rhTRAIL treatments. Ratios greater than one represent a pro-apoptotic profile, while ratios lower than one represent an anti-apoptotic profile (28,29,30). The ratio between BAX and BCL-2 expression in the TOV-21G cells treated with cisplatin was 3.37.…”
Section: ' Discussionmentioning
confidence: 99%
“…Considering these two targets are antagonistic in the apoptosis pathway, BAX:BCL-2 expression ratios were calculated to define the apoptotic profile of both cell lines in response to cisplatin and rhTRAIL treatments. Ratios greater than one represent a pro-apoptotic profile, while ratios lower than one represent an anti-apoptotic profile (28,29,30). The ratio between BAX and BCL-2 expression in the TOV-21G cells treated with cisplatin was 3.37.…”
Section: ' Discussionmentioning
confidence: 99%
“…Houve assim, a redução do estágio displásico juntamente com a taxa reduzida de proliferação celular e o aumento do apoptose, à regulação negativa da expressão de c-Myc, H-ras e Bcl2, juntamente com a regulação positiva de P53, Bax e expressão ativa de Caspase-3 nas lesões cutâneas. Já o Bax é considerado um regulador do processo de apoptose, sendo ativado pela p53, e atua regulando a apoptose esta negativamente ou positivamente dependendo de sua proteína ligante (Chiu, Xue, Usuda Azizuddin & Oleinick, 2003;Faria, Patrocínio, Filho & Rabenhorst, 2006).…”
Section: Resultsunclassified
“…Impairment of myelocytomatosis oncogene ( MYC ) expression occurs in a broad range of human cancers, indicating a crucial role in tumor progression [ 133 , 134 ]. The MYC gene, located on chromosome 8q24, encoding a transcriptional factor, plays a key role in the regulation of cell cycle progression, growth, proliferation and apoptosis [ 135 , 136 ].…”
Section: Helicobacter Pylori Infection and Dgcmentioning
confidence: 99%